In May 2011, Russian biotechnological company Trans-Technologies, Ltd acquired patent for bioactive wound dressing. This is a new, improved variant of the “artificial human skin” – collagen-based biomaterial for skin wound healing.

The story of this innovative product began in 2006 when the development of a first version of wound dressing, "Neoskin", commenced. For this project Trans-Technologies organized isolation, purification and culture of human skin cells. In addition, process of collagen purification from calf skin was established. At the turn of the 2008 "Neoskin" passed clinical trials and was eligible for registration procedure.

And it was quite worthy of release and therapeutic use. Clinical trials proved "Neoskin" to be highly effective in combination therapy of severe burns, its application significantly accelerating skin regeneration, reducing complications frequency, shortening in-hospital time. Sometimes it really saves life: a few patients with 70% burns were enrolled in "Neoskin" therapy group and eventually were healed and returned to life. Moreover, this bioactive wound dressing turned out to be effective in trophic ulcers treatment: even in some hopeless chronic cases repair was observed and new skin appeared in the previously necrotic areas.

However, Trans-Technologies did not file a patent application. The fact of the matter is that the idea of such wound dressing is not novel, and, actually, similar products are old-established in the other countries.